Expression of tumor necrosis factor-alpha and cyclooxygenase-2 mRNA in porcine split-thickness wounds treated with epidermal growth factor by quantitative real-time PCR.
Epidermal growth factor (EGF) accelerates the re-epithelialization of damaged epidermal cell layers in a wound, so it especially shortens the duration of wound healing. The effect of EGF on pro-inflammatory cytokines, tumor necrosis factor-alpha (TNF-alpha) and cyclooxygenase-2 (COX-2), levels during wound healing has not been reported. We investigated the relationship between exogenous EGF treatment and the expression of TNF-alpha and COX-2 mRNA in porcine split-thickness wounds by real-time PCR. Twenty split-thickness wounds were created on the back of five pigs. Fifteen wounds were treated twice daily with EGF ointments (1 microg/g, 10 microg/g, and 50 microg/g) for 10 days and five wounds were untreated. Healing time until full-epithelialization was evaluated. We performed a quantitative analysis of TNF-alpha and COX-2 mRNA expression in wound biopsies using real-time PCR. Topical application of 1 microg/g EGF accelerated re-epithelialization more than treatments of EGF at 10 microg/g and 50 microg/g, and no treatment. The levels of TNF-alpha and COX-2 mRNA were significantly greater in wounds treated with 1 microg/g than those with 10 microg/g and 50 microg/g EGF, and no treatment. Topical treatment of EGF influences the level of TNF-alpha and COX-2 mRNA within porcine split-thickness wounds. EGF-dependent slightly up-regulation of TNF-alpha and COX-2 mRNA expression during the inflammatory phase of healing may create an optimal molecular environment for wound healing.
Jung
Kwonil
K
Department of Pharmacology and Toxicology, Institute of Bioscience and Biotechnology, Daewoong Pharmaceutical Co. Ltd, 501-2, Samgye-Ri, Pogok-Myun, Kyounggi-Do 449-814, Republic of Korea. logon0714@hanmail.net
Park
Hyun-Jin
HJ
Kim
Yeon-Hwa
YH
Hong
Joon-Pio
JP
D000818:Animals; D051546:Cyclooxygenase 2 / Q000235:genetics*; D004305:Dose-Response Relationship, Drug; D004815:Epidermal Growth Factor / Q000627:therapeutic use*; D005786:Gene Expression Regulation / Q000187:drug effects*; D016133:Polymerase Chain Reaction / Q000662:veterinary; D012333:RNA, Messenger / Q000235:genetics / Q000378:metabolism; D013552:Swine; D013553:Swine Diseases / Q000188:drug therapy* / Q000235:genetics*; D014409:Tumor Necrosis Factor-alpha / Q000235:genetics*; D014945:Wound Healing / Q000187:drug effects* / Q000235:genetics; D014947:Wounds and Injuries / Q000188:drug therapy / Q000235:genetics / Q000662:veterinary
D012333:RNA, Messenger; D014409:Tumor Necrosis Factor-alpha; D004815:Epidermal Growth Factor; D051546:Cyclooxygenase 2